EHS
EHS

Roche immunotherapy fails its first test



Hello, everyone, and how are you this fine, sunny morning? The middle of the week has arrived, as you may know, so why not celebrate with a delicious cup of stimulation? After all, you made is this far, which is a likely sign of surviving another few days. Our choice today is salted caramel mocha. And of course, no prescription is required, which is a good thing. And while you drink up, you can peruse some of the tidbits we have assembled to help you start the day. Hope you conquer the world and, as always, do keep in touch. …

Roche disclosed that an experimental cancer immunotherapy directed against a target called TIGIT failed to slow the progression of a less common but aggressive type of lung cancer, STAT says. The negative result is the first from a group of late-stage clinical trials that the company is conducting for its anti-TIGIT drug called tiragolumab. Roche invested heavily in the drug because of its potential to greatly expand the pool of patients who might benefit from treatments that work by activating the immune system to find and kill tumors. Small cell lung cancer represents approximately 10%-15% of all lung cancer cases and is particularly aggressive and difficult to treat.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED





Source link

EHS
Back to top button